Pfizer Inc. (PFE)
Pfizer (PFE) Stock Slides as Market Rises: Facts to Know Before You Trade
Pfizer (PFE) concluded the recent trading session at $27.93, signifying a -0.43% move from its prior day's close.
Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births
Pfizer's respiratory syncytial virus (RSV) vaccine for pregnant women was not tied to a higher risk of pre-term or early births, according to a study published on Monday that analyzed real-world use of the shots.
Pfizer: The Inflection Point Is Here
Pfizer's recent financial performance and Wall Street analysts' expectations around the upcoming quarterly earnings release suggest that we are currently at an inflection point. The company's current pipeline of new product developments looks promising, and two recent FDA approvals underscore its ability to deliver new products to the market. I expect more full-year EPS guidance upgrades soon, as it appears that the company is moving ahead of management's initial cost-cutting plans.
Want $1,000 in Dividend Income? Here's How Much You Have to Invest in Pfizer Stock
Much of Pfizer's revenue is driven by therapies with only modest competition. This stock is also developing a very impressive dividend-growth track record.
Down 55%, Is Pfizer a Good Dividend Stock to Buy on the Dip?
Despite a tanking stock price, Pfizer has raised its dividend for 15 consecutive years. Pfizer's profits are off their peak but more than sufficient to continue raising the dividend.
Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Pharmaceutical giant Pfizer Inc. NYSE: PFE has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy makers Novo Nordisk A/S NYSE: NVO and Mounjaro and Zepbound makers Eli Lilly & Co. NYSE: LLY. Pfizer had failed in its previous attempts to create a viable GLP-1 contender.
1 Underwhelming Stat That May Have You Thinking Twice About Buying Pfizer's Stock
Pfizer is in the midst of transition as it faces multiple patent cliffs. The company's growth strategy suggests that the business could be bigger by the end of the decade, but not necessarily by a whole lot.
UK court gives mixed ruling in Pfizer v Moderna COVID vaccine patents case
London's High Court on Tuesday ruled that one of Moderna's patents relating to technology key to the development of vaccines for COVID-19 was invalid, but that another was valid and had been infringed by Pfizer and BioNTech's rival vaccine.
Pfizer: It Could Be A Bargain
When excluding sales Pfizer generated due to COVID-19 vaccines and medication, the business is reporting solid growth. Especially the oncology business will drive growth in the years to come, and the Seagan acquisition might also contribute. With its high dividend yield and rather undervalued stock, PFE stock is a "Buy" at this point.
Pfizer And Moderna Vaccines Not Linked To Birth Defects, Study Finds
There is no evidence of major birth defects in babies born to mothers vaccinated against COVID-19 during the first trimester of pregnancy, according to new research published in JAMA Pediatrics on Monday, underscoring the safety of vaccination during pregnancy amid mounting evidence of the severe health risks infections can cause for mothers and babies.
Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod
Pfizer (PFE) and BioNTech's Omicron JN.1-adapted COVID-19 vaccine gets the Committee for Medicinal Products for Human Use's positive opinion recommending marketing authorization.
